Importance of HER2 status determination in advanced gastric cancer: A case study
DOI:
https://doi.org/10.22516/25007440.503Keywords:
Advanced gastric cancer, Treatment, Trastuzumab, HER2Abstract
Advanced gastric cancer (AGC) is an entity that encompasses two distinct clinical situations: locally advanced
unresectable gastric cancer and metastatic disease, with chemotherapy as the standard treatment. HER2
overexpression can occur in 9% to 38% of the cases with this disease and has been the first predictive
biomarker used for trastuzumab-targeted therapy in patients with advanced gastric and gastroesophageal
tumors. This article presents a patient with AGC and positive HER2 treated with conventional chemotherapy
plus trastuzumab as targeted therapy with adequate clinical response.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648. https://doi.org/10.1016/S0140-6736(20)31288-5
Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open. 2017;2(3):e000206. https://doi.org/10.1136/esmoopen-2017-000206
Oliveros R, Facundo H, Bonilla CA, Sánchez Pedraza R. Terapia de conversión en Cáncer Gástrico estadio IV. A propósito de un caso. Rev Colomb Gastroenterol. 2018;33(1):66-67. https://doi.org/10.22516/25007440.233
Wang H B, Liao X F, Zhang J. Clinicopathological factors associated with HER2 positive gastric Cancer. A meta-analysis. Medicine 2017;96(44):1-5. https://doi.org/10.1097/MD.0000000000008437
Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1-12. https://doi.org/10.1007/s10120-013-0252-z
Battaglin F, Naseem M, Puccini A, Lenz HJ. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int. 2018;18:99. https://doi.org/10.1186/s12935-018-0594-z
Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y, Komine K, Saijo K, Takahashi S, Takahashi M, Shirota H, Ohori H, Gamoh M, Ishioka C. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis. Tohoku J Exp Med. 2018;245(2):123-129. https://doi.org/10.1620/tjem.245.123
Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-50. https://doi.org/10.1038/modpathol.2011.198
Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7(1):123-133. https://doi.org/10.1002/cam4.1274
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-84. https://doi.org/10.1007/s10120-014-0402-y
Fugazzola P, Ansaloni L, Sartelli M, Catena F, Cicuttin E, Leandro G, De’ Angelis GL, Gaiani F, Di Mario F, Tomasoni M, Coccolini F. Advanced gastric cancer: the value of surgery. Acta Biomed. 2018;89(8-S):110-116. https://doi.org/10.23750/abm.v89i8-S.7897
Ciardello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160-1174. https://doi.org/10.1056/NEJMra0707704
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513-6. https://doi.org/10.1038/312513a0
Hudis C. Trastuzumab - Mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51. https://doi.org/10.1056/NEJMra043186
Dong CX, Fu JF, Ye XY, Li XF, Zhong X, Yuan Y. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol. 2014 Sep 14;20(34):12355-8. https://doi.org/10.3748/wjg.v20.i34.12355
Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol 2016;22(19):4619-4625. https://doi.org/10.3748/wjg.v22.i19.4619
Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G. HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol. 2017;143(5):835-841. https://doi.org/10.1007/s00432-017-2374-x
Bouché O, Penault-Llorca F. HER2 et cancer de l’estomac: une nouvelle cible thérapeutique pour le trastuzumab. Bull Cancer. 2010;97(12):1429-40. https://doi.org/10.1684/bdc.2010.1224
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol. 2010;3:31. https://doi.org/10.1186/1756-8722-3-31
García C, Uribe C, Niño P, Salazar D, Vásquez L. Expresión de Her2/neu en carcinoma gástrico en el área metropolitana de Bucaramanga en el periodo 2006 a 2009. Méd UIS. 2013;26(2):21-28.
Alvarado I, Gil S, Ruelas A, Villaverde D, Montes J, Medrano R. Evaluación por inmunohistoquímica de la expresión del HER2 en cáncer gástrico. Estudio clínico-patológico de 93 casos. Cirugía y Cirujanos. 2017;85(6):504-509. https://doi.org/10.1016/j.circir.2016.11.016
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
